Background: Cutaneous lesions are important as a diagnostic aid as these account for 4 out of 11 revised American Rheumatism Association criteria for disease classification Cutaneous manifestation of systemic lupus erythematosus (74.4%) and most patients had Butterfly rash (48.8%), Photosensitivity (41.9%), acute cutaneous lupus erythematosus (SCLE) (32.6%), Discoid lupus (20.9%), Nail lesions (16.3%), Alopecia (23.3%), oral nasal ulcer (37.2%), purpuric rash (23.3%), Raynaud phenomenon (16.3%), Livedo reticularis (9.3%), Telangiectasia’s (4.6%), and Urticarial lesion (2.3%). Lupus profundus (2.3%), Cutaneous manifestation of systemic lupus erythematosus are association with disease activity (97.7%), Cutaneous manifestation of systemic lupus erythematosus are association with musculoskeletal (MSK) (62.8%), Renal disease (27.9%), Hematologic disease (23.3%), Serositis (9.3%), Neurologic disease (14%), and cardiac disease (9.3%). Results: Cutaneous manifestation of systemic lupus erythematosus are association with positive ANA (90.3%) and negative ANA (9.3%), positive ds DNA (74.4%), positive Anti-Ro (69.8%), positive Anti-La (9.3%), positive Anti-SM (48.8%), and positive Anti-RNP (39.5%%) outcome of cutaneous manifestation of systemic lupus are skin atrophy and scarring (27.9%), pigmentation (25.6%) and alopecia (23.3%). Conclusion: The cutaneous lesions can provide valuable diagnosis of systemic lupus erythematosus. The most cutaneous manifestations are epidermal lesion then mucous-cutaneous lesion then vascular lesion, are associated with disease activity, and associated with high titer auto antibodies.